Posted 3/7/2024, 6:15:13 PM
Novo Nordisk's New Weight Loss Drug Shows Double the Efficacy of Top Seller
- Novo Nordisk's new weight loss drug, Amycretin, showed 13% weight loss in 12 weeks, outperforming top seller Wegovy (6% weight loss)
- Amycretin's high efficacy could cannibalize Wegovy sales unless Wegovy is made more attractive through pricing changes
- Obesity drugs are currently very expensive without insurance ($1,350 for 28-day Wegovy supply)
- Novo Nordisk working with Cigna to improve health insurance coverage of obesity treatments
- Wall Street analysts have a Moderate Buy rating on Novo Nordisk stock, with $118.80 average price target implying 13% downside risk